FDA Approves Bristol Myers Squibb, Bluebird Bio's Multiple Myeloma CAR T-Cell Therapy Abecma

NEW YORK – The US Food and Drug Administration on Friday approved Bristol Myers Squibb and Bluebird Bio's CAR T-cell therapy, idecabtagene vicleucel (Abecma), for patients with relapsed or refractory multiple myeloma who have previously received at least four lines of treatment, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody.